APO Research
Talk to an analyst

APO RESEARCH · REPORT

Long Acting Beta 2 Agonist

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Long Acting Beta 2 Agonist Industry Growth and Trends Forecast to 2032

20 December 202592 pages

Choose your research edition.

Industry ResearchLong Acting Beta 2 Agonist Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Long Acting Beta 2 Agonist Industry Growth and Trends Forecast to 203292 pages · $3,450 USDMarket StructureGlobal Long Acting Beta 2 Agonist Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032188 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Long Acting Beta 2 Agonist Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Long Acting Beta 2 Agonist Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Long Acting Beta 2 Agonist market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Long Acting Beta 2 Agonist is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Long Acting Beta 2 Agonist is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Long Acting Beta 2 Agonist is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Long Acting Beta 2 Agonist include GSK, Teva, Novartis, Chiesi, AstraZeneca, Organon and Boehringer Ingelheim, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Long Acting Beta 2 Agonist market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Long Acting Beta 2 Agonist market size, estimates, and forecasts are presented in terms of sales volume (k units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Long Acting Beta 2 Agonist market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Long Acting Beta 2 Agonist.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Long Acting Beta 2 Agonist market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Long Acting Beta 2 Agonist Market by Company

GSK

Teva

Novartis

Chiesi

AstraZeneca

Organon

Boehringer Ingelheim

Long Acting Beta 2 Agonist Segment by Type

Serevent

Foradil

Other

Long Acting Beta 2 Agonist Segment by Application

COPD

Asthma

Other

Long Acting Beta 2 Agonist Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Long Acting Beta 2 Agonist market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Long Acting Beta 2 Agonist and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Long Acting Beta 2 Agonist.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Long Acting Beta 2 Agonist manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Long Acting Beta 2 Agonist in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Serevent Table 2. Major Company of Foradil Table 3. Major Company of Other Table 4. Global Long Acting Beta 2 Agonist Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Long Acting Beta 2 Agonist Sales by Type (2021-2026) & (k units) Table 6. Global Long Acting Beta 2 Agonist Sales Market Share in Volume by Type (2021-2026) Table 7. Global Long Acting Beta 2 Agonist Sales by Type (2021-2026) & (US$ Million) Table 8. Global Long Acting Beta 2 Agonist Sales Market Share in Value by Type (2021-2026) Table 9. Global Long Acting Beta 2 Agonist Price by Type (2021-2026) & (US$/unit) Table 10. Global Long Acting Beta 2 Agonist Sales by Type (2027-2032) & (k units) Table 11. Global Long Acting Beta 2 Agonist Sales Market Share in Volume by Type (2027-2032) Table 12. Global Long Acting Beta 2 Agonist Sales by Type (2027-2032) & (US$ Million) Table 13. Global Long Acting Beta 2 Agonist Sales Market Share in Value by Type (2027-2032) Table 14. Global Long Acting Beta 2 Agonist Price by Type (2027-2032) & (US$/unit) Table 15. North America Long Acting Beta 2 Agonist Sales by Type (2021-2026) & (k units) Table 16. North America Long Acting Beta 2 Agonist Sales by Type (2021-2026) & (US$ Million) Table 17. Europe Long Acting Beta 2 Agonist Sales by Type (2021-2026) & (k units) Table 18. Europe Long Acting Beta 2 Agonist Sales by Type (2021-2026) & (US$ Million) Table 19. Asia-Pacific Long Acting Beta 2 Agonist Sales by Type (2021-2026) & (k units) Table 20. Asia-Pacific Long Acting Beta 2 Agonist Sales by Type (2021-2026) & (US$ Million) Table 21. Latin America Long Acting Beta 2 Agonist Sales by Type (2021-2026) & (k units) Table 22. Latin America Long Acting Beta 2 Agonist Sales by Type (2021-2026) & (US$ Million) Table 23. Middle East and Africa Long Acting Beta 2 Agonist Sales by Type (2021-2026) & (k units) Table 24. Middle East and Africa Long Acting Beta 2 Agonist Sales by Type (2021-2026) & (US$ Million) Table 25. Long Acting Beta 2 Agonist Industry Trends Table 26. Long Acting Beta 2 Agonist Industry Drivers Table 27. Long Acting Beta 2 Agonist Industry Opportunities and Challenges Table 28. Long Acting Beta 2 Agonist Industry Restraints Table 29. Global Long Acting Beta 2 Agonist Sales Revenue by Company (US$ Million) & (2021-2026) Table 30. Global Long Acting Beta 2 Agonist Revenue Market Share by Company (2021-2026) Table 31. Global Long Acting Beta 2 Agonist Sales by Company (2021-2026) & (k units) Table 32. Global Long Acting Beta 2 Agonist Sales Share by Company (2021-2026) Table 33. Global Long Acting Beta 2 Agonist Market Price by Company (2021-2026) & (US$/unit) Table 34. Global Long Acting Beta 2 Agonist Industry Company Ranking, 2024 VS 2025 VS 2026 Table 35. Global Long Acting Beta 2 Agonist Major Company Production Sites and Headquarters Table 36. Global Long Acting Beta 2 Agonist Company, Product Type & Application Table 37. Global Long Acting Beta 2 Agonist Company Establishment Date Table 38. Global Company Market Concentration Ratio (CR5 and HHI) Table 39. Global Long Acting Beta 2 Agonist by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 40. Global Long Acting Beta 2 Agonist Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 41. Global Long Acting Beta 2 Agonist Sales by Region (2021-2026) & (k units) Table 42. Global Long Acting Beta 2 Agonist Sales Market Share in Volume by Region (2021-2026) Table 43. Global Long Acting Beta 2 Agonist Sales by Region (2021-2026) & (US$ Million) Table 44. Global Long Acting Beta 2 Agonist Sales Market Share in Value by Region (2021-2026) Table 45. Global Long Acting Beta 2 Agonist Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 46. Global Long Acting Beta 2 Agonist Sales by Region (2027-2032) & (k units) Table 47. Global Long Acting Beta 2 Agonist Sales Market Share in Volume by Region (2027-2032) Table 48. Global Long Acting Beta 2 Agonist Sales by Region (2027-2032) & (US$ Million) Table 49. Global Long Acting Beta 2 Agonist Sales Market Share in Value by Region (2027-2032) Table 50. Global Long Acting Beta 2 Agonist Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2027-2032) Table 51. Global Long Acting Beta 2 Agonist Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 52. Global Long Acting Beta 2 Agonist Sales by Application (2021-2026) & (k units) Table 53. Global Long Acting Beta 2 Agonist Sales Market Share in Volume by Application (2021-2026) Table 54. Global Long Acting Beta 2 Agonist Sales by Application (2021-2026) & (US$ Million) Table 55. Global Long Acting Beta 2 Agonist Sales Market Share in Value by Application (2021-2026) Table 56. Global Long Acting Beta 2 Agonist Price by Application (2021-2026) & (US$/unit) Table 57. Global Long Acting Beta 2 Agonist Sales by Application (2027-2032) & (k units) Table 58. Global Long Acting Beta 2 Agonist Sales Market Share in Volume by Application (2027-2032) Table 59. Global Long Acting Beta 2 Agonist Sales by Application (2027-2032) & (US$ Million) Table 60. Global Long Acting Beta 2 Agonist Sales Market Share in Value by Application (2027-2032) Table 61. Global Long Acting Beta 2 Agonist Price by Application (2027-2032) & (US$/unit) Table 62. North America Long Acting Beta 2 Agonist Sales by Application (2021-2026) & (k units) Table 63. North America Long Acting Beta 2 Agonist Sales by Application (2021-2026) & (US$ Million) Table 64. Europe Long Acting Beta 2 Agonist Sales by Application (2021-2026) & (k units) Table 65. Europe Long Acting Beta 2 Agonist Sales by Application (2021-2026) & (US$ Million) Table 66. Asia-Pacific Long Acting Beta 2 Agonist Sales by Application (2021-2026) & (k units) Table 67. Asia-Pacific Long Acting Beta 2 Agonist Sales by Application (2021-2026) & (US$ Million) Table 68. Latin America Long Acting Beta 2 Agonist Sales by Application (2021-2026) & (k units) Table 69. Latin America Long Acting Beta 2 Agonist Sales by Application (2021-2026) & (US$ Million) Table 70. Middle East and Africa Long Acting Beta 2 Agonist Sales by Application (2021-2026) & (k units) Table 71. Middle East and Africa Long Acting Beta 2 Agonist Sales by Application (2021-2026) & (US$ Million) Table 72. GSK Company Information Table 73. GSK Business Overview Table 74. GSK Long Acting Beta 2 Agonist Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 75. GSK Long Acting Beta 2 Agonist Product Portfolio Table 76. GSK Recent Development Table 77. Teva Company Information Table 78. Teva Business Overview Table 79. Teva Long Acting Beta 2 Agonist Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 80. Teva Long Acting Beta 2 Agonist Product Portfolio Table 81. Teva Recent Development Table 82. Novartis Company Information Table 83. Novartis Business Overview Table 84. Novartis Long Acting Beta 2 Agonist Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 85. Novartis Long Acting Beta 2 Agonist Product Portfolio Table 86. Novartis Recent Development Table 87. Chiesi Company Information Table 88. Chiesi Business Overview Table 89. Chiesi Long Acting Beta 2 Agonist Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 90. Chiesi Long Acting Beta 2 Agonist Product Portfolio Table 91. Chiesi Recent Development Table 92. AstraZeneca Company Information Table 93. AstraZeneca Business Overview Table 94. AstraZeneca Long Acting Beta 2 Agonist Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 95. AstraZeneca Long Acting Beta 2 Agonist Product Portfolio Table 96. AstraZeneca Recent Development Table 97. Organon Company Information Table 98. Organon Business Overview Table 99. Organon Long Acting Beta 2 Agonist Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 100. Organon Long Acting Beta 2 Agonist Product Portfolio Table 101. Organon Recent Development Table 102. Boehringer Ingelheim Company Information Table 103. Boehringer Ingelheim Business Overview Table 104. Boehringer Ingelheim Long Acting Beta 2 Agonist Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 105. Boehringer Ingelheim Long Acting Beta 2 Agonist Product Portfolio Table 106. Boehringer Ingelheim Recent Development Table 107. North America Long Acting Beta 2 Agonist Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 108. North America Long Acting Beta 2 Agonist Sales by Country (2021-2026) & (k units) Table 109. North America Long Acting Beta 2 Agonist Sales Market Share by Country (2021-2026) Table 110. North America Long Acting Beta 2 Agonist Sales Forecast by Country (2027-2032) & (k units) Table 111. North America Long Acting Beta 2 Agonist Sales Market Share Forecast by Country (2027-2032) Table 112. North America Long Acting Beta 2 Agonist Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 113. North America Long Acting Beta 2 Agonist Market Size by Country (2021-2026) & (US$ Million) Table 114. North America Long Acting Beta 2 Agonist Market Share by Country (2021-2026) Table 115. North America Long Acting Beta 2 Agonist Market Size Forecast by Country (2027-2032) & (US$ Million) Table 116. North America Long Acting Beta 2 Agonist Market Share Forecast by Country (2027-2032) Table 117. Europe Long Acting Beta 2 Agonist Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 118. Europe Long Acting Beta 2 Agonist Sales by Country (2021-2026) & (k units) Table 119. Europe Long Acting Beta 2 Agonist Sales Market Share by Country (2021-2026) Table 120. Europe Long Acting Beta 2 Agonist Sales Forecast by Country (2027-2032) & (k units) Table 121. Europe Long Acting Beta 2 Agonist Sales Market Share Forecast by Country (2027-2032) Table 122. Europe Long Acting Beta 2 Agonist Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 123. Europe Long Acting Beta 2 Agonist Market Size by Country (2021-2026) & (US$ Million) Table 124. Europe Long Acting Beta 2 Agonist Market Share by Country (2021-2026) Table 125. Europe Long Acting Beta 2 Agonist Market Size Forecast by Country (2027-2032) & (US$ Million) Table 126. Europe Long Acting Beta 2 Agonist Market Share Forecast by Country (2027-2032) Table 127. Asia-Pacific Long Acting Beta 2 Agonist Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 128. Asia-Pacific Long Acting Beta 2 Agonist Sales by Country (2021-2026) & (k units) Table 129. Asia-Pacific Long Acting Beta 2 Agonist Sales Market Share by Country (2021-2026) Table 130. Asia-Pacific Long Acting Beta 2 Agonist Sales Forecast by Country (2027-2032) & (k units) Table 131. Asia-Pacific Long Acting Beta 2 Agonist Sales Market Share Forecast by Country (2027-2032) Table 132. Asia-Pacific Long Acting Beta 2 Agonist Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 133. Asia-Pacific Long Acting Beta 2 Agonist Market Size by Country (2021-2026) & (US$ Million) Table 134. Asia-Pacific Long Acting Beta 2 Agonist Market Share by Country (2021-2026) Table 135. Asia-Pacific Long Acting Beta 2 Agonist Market Size Forecast by Country (2027-2032) & (US$ Million) Table 136. Asia-Pacific Long Acting Beta 2 Agonist Market Share Forecast by Country (2027-2032) Table 137. Latin America Long Acting Beta 2 Agonist Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 138. Latin America Long Acting Beta 2 Agonist Sales by Country (2021-2026) & (k units) Table 139. Latin America Long Acting Beta 2 Agonist Sales Market Share by Country (2021-2026) Table 140. Latin America Long Acting Beta 2 Agonist Sales Forecast by Country (2027-2032) & (k units) Table 141. Latin America Long Acting Beta 2 Agonist Sales Market Share Forecast by Country (2027-2032) Table 142. Latin America Long Acting Beta 2 Agonist Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 143. Latin America Long Acting Beta 2 Agonist Market Size by Country (2021-2026) & (US$ Million) Table 144. Latin America Long Acting Beta 2 Agonist Market Share by Country (2021-2026) Table 145. Latin America Long Acting Beta 2 Agonist Market Size Forecast by Country (2027-2032) & (US$ Million) Table 146. Latin America Long Acting Beta 2 Agonist Market Share Forecast by Country (2027-2032) Table 147. Middle East and Africa Long Acting Beta 2 Agonist Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 148. Middle East and Africa Long Acting Beta 2 Agonist Sales by Country (2021-2026) & (k units) Table 149. Middle East and Africa Long Acting Beta 2 Agonist Sales Market Share by Country (2021-2026) Table 150. Middle East and Africa Long Acting Beta 2 Agonist Sales Forecast by Country (2027-2032) & (k units) Table 151. Middle East and Africa Long Acting Beta 2 Agonist Sales Market Share Forecast by Country (2027-2032) Table 152. Middle East and Africa Long Acting Beta 2 Agonist Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 153. Middle East and Africa Long Acting Beta 2 Agonist Market Size by Country (2021-2026) & (US$ Million) Table 154. Middle East and Africa Long Acting Beta 2 Agonist Market Share by Country (2021-2026) Table 155. Middle East and Africa Long Acting Beta 2 Agonist Market Size Forecast by Country (2027-2032) & (US$ Million) Table 156. Middle East and Africa Long Acting Beta 2 Agonist Market Share Forecast by Country (2027-2032) Table 157. Key Raw Materials Table 158. Raw Materials Key Suppliers Table 159. Long Acting Beta 2 Agonist Distributors List Table 160. Long Acting Beta 2 Agonist Customers List Table 161. Research Programs/Design for This Report Table 162. Authors List of This Report Table 163. Secondary Sources Table 164. Primary Sources List of Figures Figure 1. Long Acting Beta 2 Agonist Image Figure 2. Global Long Acting Beta 2 Agonist Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Long Acting Beta 2 Agonist Market Size (2021-2032) & (US$ Million) Figure 4. Global Long Acting Beta 2 Agonist Sales (2021-2032) & (k units) Figure 5. Serevent Image Figure 6. Global Serevent Sales YoY Growth (2021-2032) & (k units) Figure 7. Foradil Image Figure 8. Global Foradil Sales YoY Growth (2021-2032) & (k units) Figure 9. Other Image Figure 10. Global Other Sales YoY Growth (2021-2032) & (k units) Figure 11. Global Long Acting Beta 2 Agonist Market Size Overview by Type (2021-2032) & (US$ Million) Figure 12. Global Long Acting Beta 2 Agonist Market Share by Type 2025 VS 2032 Figure 13. North America Long Acting Beta 2 Agonist Sales Market Share in Volume by Type in 2025 Figure 14. North America Long Acting Beta 2 Agonist Sales Market Share in Value by Type in 2025 Figure 15. Europe Long Acting Beta 2 Agonist Sales Market Share in Volume by Type in 2025 Figure 16. Europe Long Acting Beta 2 Agonist Sales Market Share in Value by Type in 2025 Figure 17. Asia-Pacific Long Acting Beta 2 Agonist Sales Market Share in Volume by Type in 2025 Figure 18. Asia-Pacific Long Acting Beta 2 Agonist Sales Market Share in Value by Type in 2025 Figure 19. Latin America Long Acting Beta 2 Agonist Sales Market Share in Volume by Type in 2025 Figure 20. Latin America Long Acting Beta 2 Agonist Sales Market Share in Value by Type in 2025 Figure 21. Middle East and Africa Long Acting Beta 2 Agonist Sales Market Share in Volume by Type in 2025 Figure 22. Middle East and Africa Long Acting Beta 2 Agonist Sales Market Share in Value by Type in 2025 Figure 23. Global Top 5 and 10 Long Acting Beta 2 Agonist Players Market Share by Revenue in 2025 Figure 24. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 25. COPD Image Figure 26. Global COPD Sales YoY Growth (2021-2032) & (k units) Figure 27. Asthma Image Figure 28. Global Asthma Sales YoY Growth (2021-2032) & (k units) Figure 29. Other Image Figure 30. Global Other Sales YoY Growth (2021-2032) & (k units) Figure 31. Global Long Acting Beta 2 Agonist Market Size Overview by Application (2021-2032) & (US$ Million) Figure 32. Global Long Acting Beta 2 Agonist Market Share by Application 2025 VS 2032 Figure 33. North America Long Acting Beta 2 Agonist Sales Market Share in Volume by Application in 2025 Figure 34. North America Long Acting Beta 2 Agonist Sales Market Share in Value by Application in 2025 Figure 35. Europe Long Acting Beta 2 Agonist Sales Market Share in Volume by Application in 2025 Figure 36. Europe Long Acting Beta 2 Agonist Sales Market Share in Value by Application in 2025 Figure 37. Asia-Pacific Long Acting Beta 2 Agonist Sales Market Share in Volume by Application in 2025 Figure 38. Asia-Pacific Long Acting Beta 2 Agonist Sales Market Share in Value by Application in 2025 Figure 39. Latin America Long Acting Beta 2 Agonist Sales Market Share in Volume by Application in 2025 Figure 40. Latin America Long Acting Beta 2 Agonist Sales Market Share in Value by Application in 2025 Figure 41. Middle East and Africa Long Acting Beta 2 Agonist Sales Market Share in Volume by Application in 2025 Figure 42. Middle East and Africa Long Acting Beta 2 Agonist Sales Market Share in Value by Application in 2025 Figure 43. North America Long Acting Beta 2 Agonist Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 44. North America Long Acting Beta 2 Agonist Sales Share by Country: 2021 VS 2025 VS 2032 Figure 45. North America Long Acting Beta 2 Agonist Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 46. North America Long Acting Beta 2 Agonist Market Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Long Acting Beta 2 Agonist Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 48. Europe Long Acting Beta 2 Agonist Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Long Acting Beta 2 Agonist Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Europe Long Acting Beta 2 Agonist Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Long Acting Beta 2 Agonist Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 52. Asia-Pacific Long Acting Beta 2 Agonist Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Long Acting Beta 2 Agonist Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Asia-Pacific Long Acting Beta 2 Agonist Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Long Acting Beta 2 Agonist Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 56. Latin America Long Acting Beta 2 Agonist Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Long Acting Beta 2 Agonist Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Latin America Long Acting Beta 2 Agonist Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Long Acting Beta 2 Agonist Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 60. Middle East and Africa Long Acting Beta 2 Agonist Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Long Acting Beta 2 Agonist Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Middle East and Africa Long Acting Beta 2 Agonist Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Long Acting Beta 2 Agonist Value Chain Figure 64. Key Raw Materials Price Figure 65. Manufacturing Cost Structure Figure 66. Long Acting Beta 2 Agonist Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Serevent
  • Foradil
  • Other
Applications
  • COPD
  • Asthma
  • Other
Companies covered
  • GSK
  • Teva
  • Novartis
  • Chiesi
  • AstraZeneca
  • Organon
  • Boehringer Ingelheim

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Long Acting Beta 2 Agonist Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Long Acting Beta 2 Agonist Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Long Acting Beta 2 Agonist Market by Type
  6. 1.3.1 Serevent
  7. 1.3.2 Foradil
  8. 1.3.3 Other
  9. 1.4 Global Long Acting Beta 2 Agonist Market Size by Type
  10. 1.4.1 Global Long Acting Beta 2 Agonist Market Size Overview by Type (2021-2032)
  11. 1.4.2 Global Long Acting Beta 2 Agonist Historic Market Size Review by Type (2021-2026)
  12. 1.4.3 Global Long Acting Beta 2 Agonist Forecasted Market Size by Type (2027-2032)
  13. 1.5 Key Regions Market Size by Type
  14. 1.5.1 North America Long Acting Beta 2 Agonist Sales Breakdown by Type (2021-2026)
  15. 1.5.2 Europe Long Acting Beta 2 Agonist Sales Breakdown by Type (2021-2026)
  16. 1.5.3 Asia-Pacific Long Acting Beta 2 Agonist Sales Breakdown by Type (2021-2026)
  17. 1.5.4 South America Long Acting Beta 2 Agonist Sales Breakdown by Type (2021-2026)
  18. 1.5.5 Middle East and Africa Long Acting Beta 2 Agonist Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Long Acting Beta 2 Agonist Industry Trends
  2. 2.2 Long Acting Beta 2 Agonist Industry Drivers
  3. 2.3 Long Acting Beta 2 Agonist Industry Opportunities and Challenges
  4. 2.4 Long Acting Beta 2 Agonist Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Long Acting Beta 2 Agonist Revenue (2021-2026)
  2. 3.2 Global Top Players by Long Acting Beta 2 Agonist Sales (2021-2026)
  3. 3.3 Global Top Players by Long Acting Beta 2 Agonist Price (2021-2026)
  4. 3.4 Global Long Acting Beta 2 Agonist Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Long Acting Beta 2 Agonist Major Company Production Sites & Headquarters
  6. 3.6 Global Long Acting Beta 2 Agonist Company, Product Type & Application
  7. 3.7 Global Long Acting Beta 2 Agonist Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Long Acting Beta 2 Agonist Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Long Acting Beta 2 Agonist Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Long Acting Beta 2 Agonist Tier 1, Tier 2, and Tier 3
4 Long Acting Beta 2 Agonist Regional Status and Outlook
  1. 4.1 Global Long Acting Beta 2 Agonist Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Long Acting Beta 2 Agonist Historic Market Size by Region
  3. 4.2.1 Global Long Acting Beta 2 Agonist Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Long Acting Beta 2 Agonist Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Long Acting Beta 2 Agonist Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Long Acting Beta 2 Agonist Forecasted Market Size by Region
  7. 4.3.1 Global Long Acting Beta 2 Agonist Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Long Acting Beta 2 Agonist Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Long Acting Beta 2 Agonist Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Long Acting Beta 2 Agonist by Application
  1. 5.1 Long Acting Beta 2 Agonist Market by Application
  2. 5.1.1 COPD
  3. 5.1.2 Asthma
  4. 5.1.3 Other
  5. 5.2 Global Long Acting Beta 2 Agonist Market Size by Application
  6. 5.2.1 Global Long Acting Beta 2 Agonist Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Long Acting Beta 2 Agonist Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Long Acting Beta 2 Agonist Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Long Acting Beta 2 Agonist Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Long Acting Beta 2 Agonist Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Long Acting Beta 2 Agonist Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Long Acting Beta 2 Agonist Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Long Acting Beta 2 Agonist Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 GSK
  2. 6.1.1 GSK Company Information
  3. 6.1.2 GSK Business Overview
  4. 6.1.3 GSK Long Acting Beta 2 Agonist Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 GSK Long Acting Beta 2 Agonist Product Portfolio
  6. 6.1.5 GSK Recent Developments
  7. 6.2 Teva
  8. 6.2.1 Teva Company Information
  9. 6.2.2 Teva Business Overview
  10. 6.2.3 Teva Long Acting Beta 2 Agonist Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Teva Long Acting Beta 2 Agonist Product Portfolio
  12. 6.2.5 Teva Recent Developments
  13. 6.3 Novartis
  14. 6.3.1 Novartis Company Information
  15. 6.3.2 Novartis Business Overview
  16. 6.3.3 Novartis Long Acting Beta 2 Agonist Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Novartis Long Acting Beta 2 Agonist Product Portfolio
  18. 6.3.5 Novartis Recent Developments
  19. 6.4 Chiesi
  20. 6.4.1 Chiesi Company Information
  21. 6.4.2 Chiesi Business Overview
  22. 6.4.3 Chiesi Long Acting Beta 2 Agonist Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Chiesi Long Acting Beta 2 Agonist Product Portfolio
  24. 6.4.5 Chiesi Recent Developments
  25. 6.5 AstraZeneca
  26. 6.5.1 AstraZeneca Company Information
  27. 6.5.2 AstraZeneca Business Overview
  28. 6.5.3 AstraZeneca Long Acting Beta 2 Agonist Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 AstraZeneca Long Acting Beta 2 Agonist Product Portfolio
  30. 6.5.5 AstraZeneca Recent Developments
  31. 6.6 Organon
  32. 6.6.1 Organon Company Information
  33. 6.6.2 Organon Business Overview
  34. 6.6.3 Organon Long Acting Beta 2 Agonist Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Organon Long Acting Beta 2 Agonist Product Portfolio
  36. 6.6.5 Organon Recent Developments
  37. 6.7 Boehringer Ingelheim
  38. 6.7.1 Boehringer Ingelheim Company Information
  39. 6.7.2 Boehringer Ingelheim Business Overview
  40. 6.7.3 Boehringer Ingelheim Long Acting Beta 2 Agonist Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Boehringer Ingelheim Long Acting Beta 2 Agonist Product Portfolio
  42. 6.7.5 Boehringer Ingelheim Recent Developments
7 North America by Country
  1. 7.1 North America Long Acting Beta 2 Agonist Sales by Country
  2. 7.1.1 North America Long Acting Beta 2 Agonist Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Long Acting Beta 2 Agonist Sales by Country (2021-2026)
  4. 7.1.3 North America Long Acting Beta 2 Agonist Sales Forecast by Country (2027-2032)
  5. 7.2 North America Long Acting Beta 2 Agonist Market Size by Country
  6. 7.2.1 North America Long Acting Beta 2 Agonist Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Long Acting Beta 2 Agonist Market Size by Country (2021-2026)
  8. 7.2.3 North America Long Acting Beta 2 Agonist Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Long Acting Beta 2 Agonist Sales by Country
  2. 8.1.1 Europe Long Acting Beta 2 Agonist Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Long Acting Beta 2 Agonist Sales by Country (2021-2026)
  4. 8.1.3 Europe Long Acting Beta 2 Agonist Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Long Acting Beta 2 Agonist Market Size by Country
  6. 8.2.1 Europe Long Acting Beta 2 Agonist Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Long Acting Beta 2 Agonist Market Size by Country (2021-2026)
  8. 8.2.3 Europe Long Acting Beta 2 Agonist Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Long Acting Beta 2 Agonist Sales by Country
  2. 9.1.1 Asia-Pacific Long Acting Beta 2 Agonist Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Long Acting Beta 2 Agonist Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Long Acting Beta 2 Agonist Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Long Acting Beta 2 Agonist Market Size by Country
  6. 9.2.1 Asia-Pacific Long Acting Beta 2 Agonist Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Long Acting Beta 2 Agonist Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Long Acting Beta 2 Agonist Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Long Acting Beta 2 Agonist Sales by Country
  2. 10.1.1 South America Long Acting Beta 2 Agonist Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Long Acting Beta 2 Agonist Sales by Country (2021-2026)
  4. 10.1.3 South America Long Acting Beta 2 Agonist Sales Forecast by Country (2027-2032)
  5. 10.2 South America Long Acting Beta 2 Agonist Market Size by Country
  6. 10.2.1 South America Long Acting Beta 2 Agonist Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Long Acting Beta 2 Agonist Market Size by Country (2021-2026)
  8. 10.2.3 South America Long Acting Beta 2 Agonist Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Long Acting Beta 2 Agonist Sales by Country
  2. 11.1.1 Middle East and Africa Long Acting Beta 2 Agonist Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Long Acting Beta 2 Agonist Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Long Acting Beta 2 Agonist Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Long Acting Beta 2 Agonist Market Size by Country
  6. 11.2.1 Middle East and Africa Long Acting Beta 2 Agonist Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Long Acting Beta 2 Agonist Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Long Acting Beta 2 Agonist Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Long Acting Beta 2 Agonist Value Chain Analysis
  2. 12.1.1 Long Acting Beta 2 Agonist Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Long Acting Beta 2 Agonist Production Mode & Process
  7. 12.2 Long Acting Beta 2 Agonist Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Long Acting Beta 2 Agonist Distributors
  10. 12.2.3 Long Acting Beta 2 Agonist Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst